The preclinical in vivo data described hereinclearly indicate the promise of CD133 as a radiotheranostic targetfor SCLC: [89Zr]Zr-DFO-αCD133 delineated tumor tissuewith high contrast in several advanced murine models of human disease,while [177Lu]Lu-DTPA-CHX-A′′-αCD133 exerteda clear dose-dependent therapeutic effect. The gene discussed is PROM1; the disease is neoplasm.